Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,priceHint,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,shortName,marketState,market,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 12, 2021) 4","Short Ratio (Aug 12, 2021) 4","Short % of Float (Aug 12, 2021) 4","Short % of Shares Outstanding (Aug 12, 2021) 4","Shares Short (prior month Jul 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,FOLD,16113000,266060000,63003000,,-46700000,,-51225000,42276000,69033000,-37813000,-37813000,,-8150000,,,,4525000,77413000,115226000,8380000,-8887000,,-51225000,-51225000,2364494000,572982000,213910000,23000000,19800000,786892000,2685000,-2162351000,26354000,197797000,9082000,44200000,176538000,111993000,9082000,64393000,480502000,206530000,49172000,390434000,24086000,13762000,26079000,11706000,25713000,-21000,2235000,-2610000,2500000,-8261000,-244000,-286000,-35923000,1567000,-5186000,-3966000,13146000,-366000,368509000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NGM,11.68,1630526402,0.28999996,11.265,11.7,11.22,1442306,0,"Amicus Therapeutics, Inc.",POST,us_market,-0.34246543,1630530569,11.64,-0.03999996,2.5460927,11.22 - 11.7,11.39,11.63,11.75,29,9,finmb_7009878,NasdaqGM,"Amicus Therapeutics, Inc.",USD,2197998,1597033,3.08,0.35813951,8.6 - 25.39,-13.709999,-0.53997636,8.6,25.39,1620649800,1635942600,1636374600,0.18211985,10.037102,1.6428986,0.16368257,-22.037737,-0.973,-0.53,-0.82,-14.243903,0.943,9.880555,1.7994452,3107580928,12.386003,15,America/New_York,EDT,-14400000,False,False,1.08,,,25.39,8.6,9.88,10.04,2.2M,1.6M,266.06M,,220.22M,0.52%,105.49%,27.91M,11.89,10.52%,10.47%,29.66M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-89.53%,-73.27%,-17.34%,-87.78%,281.82M,1.07,24.20%,229.84M,-198.28M,-252.3M,-0.97,,383.07M,1.44,441.74M,206.51,4.29,0.94,-200.11M,-98.27M,Value,19104,Healthcare,483,3,5,"Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.",Philadelphia,215 921 7600,PA,7,1609372800,1625097600,3,United States,http://amicusrx.com,86400,4,3675 Market Street,215 921 7900,Biotechnology
t-1,FOLD,53099000,266060000,64117000,,-64082000,,-65664000,46726000,59863000,-52584000,-52584000,,-7992000,,,,1582000,66402000,118986000,6539000,-11498000,,-65664000,-65664000,2350507000,559138000,250896000,23000000,19600000,810034000,2680000,-2111126000,25266000,197797000,8835000,43538000,184833000,99652000,8835000,65808000,502891000,232596000,44931000,389789000,18801000,16110000,87433000,-40191000,86565000,-368000,8829000,6091000,23391000,21887000,-14194000,-1153000,-72354000,1604000,741000,839000,23671000,-868000,403239000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NGM,11.68,1630526402,0.28999996,11.265,11.7,11.22,1442306,0,"Amicus Therapeutics, Inc.",POST,us_market,-0.34246543,1630530569,11.64,-0.03999996,2.5460927,11.22 - 11.7,11.39,11.63,11.75,29,9,finmb_7009878,NasdaqGM,"Amicus Therapeutics, Inc.",USD,2197998,1597033,3.08,0.35813951,8.6 - 25.39,-13.709999,-0.53997636,8.6,25.39,1620649800,1635942600,1636374600,0.18211985,10.037102,1.6428986,0.16368257,-22.037737,-0.973,-0.53,-0.82,-14.243903,0.943,9.880555,1.7994452,3107580928,12.386003,15,America/New_York,EDT,-14400000,False,False,1.08,,,25.39,8.6,9.88,10.04,2.2M,1.6M,266.06M,,220.22M,0.52%,105.49%,27.91M,11.89,10.52%,10.47%,29.66M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-89.53%,-73.27%,-17.34%,-87.78%,281.82M,1.07,24.20%,229.84M,-198.28M,-252.3M,-0.97,,383.07M,1.44,441.74M,206.51,4.29,0.94,-200.11M,-98.27M,Value,19104,Healthcare,483,3,5,"Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.",Philadelphia,215 921 7600,PA,7,1609372800,1625097600,3,United States,http://amicusrx.com,86400,4,3675 Market Street,215 921 7900,Biotechnology
t-2,FOLD,88583000,266060000,79293000,,-73594000,,-71401000,43685000,61154000,-64371000,-64371000,,-8277000,,,,-2193000,70571000,134942000,9417000,-9223000,,-71401000,-71401000,2308578000,600140000,286380000,23000000,24171000,886520000,2650000,-2045462000,35606000,197797000,20614000,42095000,163240000,129676000,20614000,67159000,579469000,320029000,46923000,389254000,19556000,17063000,-21709000,12814000,-22776000,-18000,21548000,-6459000,22254000,-47265000,-688000,3785000,-49822000,2547000,-6821000,-374000,19202000,-1067000,449793000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NGM,11.68,1630526402,0.28999996,11.265,11.7,11.22,1442306,0,"Amicus Therapeutics, Inc.",POST,us_market,-0.34246543,1630530569,11.64,-0.03999996,2.5460927,11.22 - 11.7,11.39,11.63,11.75,29,9,finmb_7009878,NasdaqGM,"Amicus Therapeutics, Inc.",USD,2197998,1597033,3.08,0.35813951,8.6 - 25.39,-13.709999,-0.53997636,8.6,25.39,1620649800,1635942600,1636374600,0.18211985,10.037102,1.6428986,0.16368257,-22.037737,-0.973,-0.53,-0.82,-14.243903,0.943,9.880555,1.7994452,3107580928,12.386003,15,America/New_York,EDT,-14400000,False,False,1.08,,,25.39,8.6,9.88,10.04,2.2M,1.6M,266.06M,,220.22M,0.52%,105.49%,27.91M,11.89,10.52%,10.47%,29.66M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-89.53%,-73.27%,-17.34%,-87.78%,281.82M,1.07,24.20%,229.84M,-198.28M,-252.3M,-0.97,,383.07M,1.44,441.74M,206.51,4.29,0.94,-200.11M,-98.27M,Value,19104,Healthcare,483,3,5,"Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.",Philadelphia,215 921 7600,PA,7,1609372800,1625097600,3,United States,http://amicusrx.com,86400,4,3675 Market Street,215 921 7900,Biotechnology
t-3,FOLD,122472000,266060000,70419000,,-63284000,,-64011000,37850000,59038000,-51727000,-51727000,,-6784000,,,,727000,67437000,119164000,8399000,-11557000,,-64011000,-64011000,2274797000,580273000,320269000,23000000,8800000,900542000,2626000,-1974061000,35335000,197797000,16907000,49453000,210631000,111727000,16907000,68015000,585277000,298451000,44828000,388584000,15767000,14764000,-153777000,-758000,-154061000,230660000,238711000,1769000,9294000,46163000,-1243000,3521000,-42008000,2496000,831000,-457000,17530000,-284000,473550000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NGM,11.68,1630526402,0.28999996,11.265,11.7,11.22,1442306,0,"Amicus Therapeutics, Inc.",POST,us_market,-0.34246543,1630530569,11.64,-0.03999996,2.5460927,11.22 - 11.7,11.39,11.63,11.75,29,9,finmb_7009878,NasdaqGM,"Amicus Therapeutics, Inc.",USD,2197998,1597033,3.08,0.35813951,8.6 - 25.39,-13.709999,-0.53997636,8.6,25.39,1620649800,1635942600,1636374600,0.18211985,10.037102,1.6428986,0.16368257,-22.037737,-0.973,-0.53,-0.82,-14.243903,0.943,9.880555,1.7994452,3107580928,12.386003,15,America/New_York,EDT,-14400000,False,False,1.08,,,25.39,8.6,9.88,10.04,2.2M,1.6M,266.06M,,220.22M,0.52%,105.49%,27.91M,11.89,10.52%,10.47%,29.66M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-89.53%,-73.27%,-17.34%,-87.78%,281.82M,1.07,24.20%,229.84M,-198.28M,-252.3M,-0.97,,383.07M,1.44,441.74M,206.51,4.29,0.94,-200.11M,-98.27M,Value,19104,Healthcare,483,3,5,"Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.",Philadelphia,215 921 7600,PA,7,1609372800,1625097600,3,United States,http://amicusrx.com,86400,4,3675 Market Street,215 921 7900,Biotechnology
